Seo Jung-jin
- Seo Jung-jin is CEO of Celltrion, a biopharmaceutical company which develops drugs to treat cancer, influenza and rheumatoid arthritis, among others.
- He cofounded the company in 2002 and took it public in 2008.
- With expectations for biosimilars high in South Korea, his Celltrion has become a favorite among investors.
- His marketing subsidiary, Celltrion Healthcare, went public on the KOSDAQ in July 2017.
- In a partnership with Teva, Celltrion received FDA approval for its biosimilar, Herzuma, which is a treatment for breast cancer.
